Objective: To evaluate the effect of Manix?, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.Methods:from hospitalized patients.Results:Microbiological assay was employed using clinical isolate of Escherichia coli samples Manix? altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) μg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix? alongside pefloxacin Cmax was (0.22±0.08) μg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) μg/h/mL while with Manix? was (2.60±0.08) μg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix? pre-treatment (P<0.05).Conclusions:The concurrent use of Manix? and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.

OBJECTIVETo evaluate the effect of Manix®, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.

METHODSMicrobiological assay was employed using clinical isolate of Escherichia coli samples from hospitalized patients.

RESULTSManix® altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) µg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix® alongside pefloxacin Cmax was (0.22±0.08) µg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) µg/h/mL while with Manix® was (2.60±0.08) µg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix® pre-treatment (P<0.05).

CONCLUSIONSThe concurrent use of Manix® and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.